Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00690456 · ClinicalTrials.gov registry record · Phase 3
Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 403
- Enrollment target
NCT00690456: Clinical Trial Phase 3 study, sponsored by Sanofi.
NCT00690456 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 403 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00690456, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 403 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the effect of rimonabant 20 mg daily when added to ongoing metformin therapy on glycemic control (HbA1c) over a 36 week period in patients with type 2 diabetes. Secondary objectives include evaluation of other markers of glycemic control, lipid profile, body weight, and abdominal obesity. Also, the trial will study the safety of rimonabant when added to metformin over a period of 47 weeks.
Interventions
- DRUG Metformin
- DRUG Rimonabant
- DRUG Placebo (for Rimonabant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Why NCT00690456 stopped before completion
NCT00690456 is an interventional study that assigns participants to a tested intervention. The registered 403 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT00690456 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00690456 about?
NCT00690456 is a clinical study titled "Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes". The primary objective of the study is to determine the effect of rimonabant 20 mg daily when added to ongoing metformin therapy on glycemic control (HbA1c) over a 36 week period in patients with type 2 diabetes. Secondary objectives include evaluation of other markers of glycemic control, lipid pro...
What is the current status of trial NCT00690456?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 403 participants. The study started on 2008-05. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00690456?
The interventions under investigation include: Metformin (DRUG), Rimonabant (DRUG), Placebo (for Rimonabant) (DRUG).
Who is sponsoring clinical trial NCT00690456?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00690456's enrollment target sits among peer trials
403 917th of 2000 higher than 1,082 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05647122 · 403 participants · Phase 1
First in Human Study of AZD9592 in Solid Tumors
- NCT05674799 · 403 participants · NA
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
- NCT06244771 · 403 participants · Phase 1
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- NCT05049057 · 404 participants · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia